Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2020 ( 10 )

2019 ( 111 )

2018 ( 430 )

2017 ( 419 )

Custom range...

Search Results: 1 - 10 of 17046 matches for " Chronic Heart Failure "
All listed articles are free for downloading (OA Articles)
Page 1 /17046
Display every page Item
The specific features of heart and vessels remodeling in patients with chronic heart failure treated with lisinopril during 6 months
N.A. Kosheleva,A.P. Rebrov
Rational Pharmacotherapy in Cardiology , 2010,
Abstract: Background. Being able to attenuate pathological remodeling, ACE inhibitors are considered to be first line medications for chronic heart failure (CHF) treatment.Aim. To study the influence of the 6-month combined therapy with lisinopril on the heart and vessels remodeling in patients with ischemic CHF.Material and Methods. 40 patients with CHF after Q-myocardial infarction were treated with lisinopril (Listril, Dr.Reddy’s, India) as a part of complex therapy. Initially and after 6 months of therapy the following findings were evaluated: the 6-minute walk test results, echocardiography parameters, main arteries rigidity, endothelium-dependent and independent vasodilatation, anticoagulant and fibrinolytic function of vascular endothelium, von Willebrand factor (VWF).Results. 6-month treatment with lisinopril showed reduction in CHF functional class in 30 % of patients and increase in left ventricle (LV) stroke volume by 3,8% and LV ejection fraction by 1%. Pulse-wave velocity reduced insignificantly from 10,2 to 9,2 m/sec and augmentation indices of aorta from 31,4% to 29,9% as well as this of brachial artery from -2,6% to -6%. Endothelium-dependent vasodilatation increased from 6,4% to 8,6% and independent vasodilatation – from 13,8% to 16,6%. VWF activity decrease was observed in 40% of CHF patients. Significant changes in anticoagulant and fibrinolytic function of vascular endothelium were not revealed.Conclusion. Lisinopril administration as a part of complex therapy of CHF patients during 6 months resulted in favorable effect on heart and vessels remodeling and was well tolerated.
Clinical approaches to interpretation of clinical trails results on beta-blockers for the treatment of patients with chronic heart failure
S.R. Giljarevskiy,I.M. Kuzmina
Rational Pharmacotherapy in Cardiology , 2010,
Abstract: Modern approaches to a choice of beta-blockers for treatment of patients with chronic heart failure depending on the statistical and clinical significance of randomized clinical trails results are considered. Beta-blocker class-effect is discussed in context of beta-blocker therapeutic tactics. Data about bisoprolol usage for prevention of sudden death in patients with left ventricle systolic dysfunction is also presented.
New Parameters of Cardiopulmonary Exercise Testing in Patients with Chronic Heart Failure: Practical Applications  [PDF]
P. Gibelin, A. Aldossari, D. Bertora, P. Moceri, T. Hugues
International Journal of Clinical Medicine (IJCM) , 2012, DOI: 10.4236/ijcm.2012.36096
Abstract: Cardiopulmonary exercise testing (CPX) has become the cornerstone of risk stratification for heart failure patients. Peak oxygen consumption (VO2) was the first CPX variable to demonstrate prognostic value and is still the most frequently analyzed variable in clinical practice. More recently, several investigations have shown that ventilatory efficiency, typically expressed as the minute ventilation/carbon dioxide production (VE/VCO2) slope, is a strong prognostic marker in patient with HF. The majority of studies report the VE/VCO2 slope to be prognostically superior to peak VO2 which underscore the clinical importance of assessing ventilatory efficiency in HF patients. Other expressions of ventilatory inefficiency like exercise oscillatory breathing (EOB), oxygen uptake efficiency slope (OUES), end-tidal carbon dioxide pressure (PET CO2) at rest, and haemodynamic responses such as heart rate recovery (HRR) are strong predictors of outcomes in patients with heart failure (HF). So there is a need for simplified approaches that integrate the additive prognostic information from cardiopulmonary exercise testing.
Stage of readiness for planned activity reveals heart failure patients at higher risk  [PDF]
Tracie R. Parish, Maria Kosma, Michael A. Welsch
Open Journal of Preventive Medicine (OJPM) , 2013, DOI: 10.4236/ojpm.2013.31015
Abstract: Few individuals with chronic heart failure (CHF) engage in regular physical activity. PURPOSE: 1) To examine stage of readiness for planned physical activity; 2) To compare estimated self-reported daily physical activity and exercise tolerance/capacity by stage of readiness; and 3) To determine the association between stages of readiness for planned physical activity, self-reported daily physical activity and exercise tolerance, in CHF patients. METHODS: One-hundred eleven CHF patients (Age: 53 ± 14 yrs; New YorkHeart Association class II/III) participated. Each participant’s stage of readiness for planned physical activity was assessed. Patients completed a self-reported daily physical activity questionnaire, and performed a six-minute walk test. RESULTS: Average left ventricular ejection fraction (LVEF) was 30.12% ± 10.72%. Twelve patients were in Precontemplation (PC),29 inContemplation (C),30 inPreparation (PR),20 inAction (A), and20 inMaintenance (M). There were no differences in age and LVEF between stages. Those classified in A/M performed more minutes in activities > 3 METs. Average 6MWD was 349 ± 118 meters, with significant differences between stages (PC, C < PR < A < M; p < 0.01). Thirty-four of 71 patients in preaction scored < 300 meters versus only 3 and 5 of 40 from A/M. CONCLUSION: The majority of CHF patients are in pre-action stages of readiness for adoption of planned physical activity. Patients in pre-action are engaged in less daily activity and have lower exercise tolerance/capacity than those in A/M. Lower exercise tolerance/capacity suggests these patients are more fragile and at greater risk for complications and early mortality. Greater emphasis should be placed on strategies
Clinical evidence of traditional Chinese medicine for the prevention and treatment of chronic heart failure  [PDF]
Shuo Zhang, Jiaying Wang, Hongcai Shang
World Journal of Cardiovascular Diseases (WJCD) , 2013, DOI: 10.4236/wjcd.2013.31A024
Abstract: Objective: To summarize clinical evidence of traditional Chinese medicine for the prevention and treatment of chronic heart failure systematically and comprehensively. MethodBy retrieving in the database of VIP, WanFang, CNKI, PubMed, Cochrane Library, the qualifying results obtained in the databases above are summarized into the grading evidence including systematic reviews, randomized controlled trials, observational studies, case studies, basic research these five levels. Results: The numbers of the articles included are 12 systematic reviews, 413 randomized controlled trials, 68 observational studies, 15 case reports and 187 fundamental researches. Conclusion: It is concluded that basing on the clinical evidence of different levels, traditional Chinese medicine has prominent ability of preventing and treatment chronic heart failure.
Hypoglycemic myocardial stunning as cause of cardiogenic shock in a patient with ischemic cardiomyopathy: A case report and review of literature  [PDF]
Khawar Maqsood, Ghazi Mirrani, Nosheen Sarwar, Amatur R. Amarah, Muhammad Rizwan Sardar, Timothy A. Shapiro
Case Reports in Clinical Medicine (CRCM) , 2013, DOI: 10.4236/crcm.2013.21024

Hypoglycemia is a common complication seen in patients with diabetes mellitus and has been proven to have adverse effects on cardiovascular mortality. Hypoglycemia can potentially lead to worsening of cardiac function in patients with ischemic heart disease. We present a case of cardiogenic shock in a patient with hypoglycemia secondary to insulin accumulation due to worsening renal function with dramatic recovery of shock once his sugars normalized.

Interventions to improve daily activity in individuals with COPD and CHF: A systematic review  [PDF]
Michael J. Shoemaker, Brian Keenoy, Brad Smith, Patrick Slotman
World Journal of Cardiovascular Diseases (WJCD) , 2013, DOI: 10.4236/wjcd.2013.33044

Introduction: The purpose was to systematically review the literature regarding interventions to improve daily activity in individuals with chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF). Methods: Articles found by searching CINAHL Plus Full-Text, PubMed, and PsycINFO databases were included in the review if the study examined the effect of exercise- and/or psychosocial-based interventions on daily activity in individuals with COPD or CHF. Article selection, data extraction, and evaluation of methodological rigor and quality were performed by two independent reviewers. Nine articles for COPD and seven articles for CHF met the inclusion criteria and were used in this review. Results: Only four of nine studies in COPD and two of seven studies in CHF resulted in improvement in daily activity, and of those, all but one study included a psychosocial-based intervention. Improvements in daily activity did not occur concurrently with changes in other outcomes such as exercise performance, quality of life, functional status, or anxiety/depression in COPD or CHF. Conclusions: Exercise-based interventions serve a limited, if any, role in improving daily activity in individuals with COPD and CHF. Disrupting the cycle of inactivity and deconditioning requires more than just addressing the deconditioning aspect of this cycle. Psychosocial-based interventions are a promising, but under-investigated, intervention.

Chronic heart failure - nursing diagnoses
Sorin Cri?an,?tefan Vesa,Teodora Ni??,Elena Buzdugan
Human & Veterinary Medicine , 2010,
Abstract: The authors present the most important nursing diagnoses in patients with chronic heartfailure. The main actual diagnoses are the following: decreased cardiac output, excess fluid volume,ineffective tissue perfusion, ineffective breathing pattern, activity intolerance, and noncompliance. Theprincipal risk diagnoses are risk of activity intolerance, fluid volume deficit, infection, medication, andskin integrity impairment.
Effect of mitral regurgitation on chronic heart failure course and structure-functional heart state (Full english text)
V.N. Larina,B.Y. Bart,M.P. Mikhaylusova,B.N. Mamtsev
Rational Pharmacotherapy in Cardiology , 2009,
Abstract: Aim. To evaluate chronic heart failure (CHF) course, functional and structural heart changes in patients with functional mitral regurgitation (MR) of various degrees.Material and methods. A total of 104 outpatients (60-85 y. o.) with CHF of functional class II-IV by NYHA and functional MR of I-II degrees and MR of III-IV degrees were included into the study groups.Results: Patients in both groups were comparable in sex, age, CHF duration, body mass index, systolic and diastolic blood pressure, clinical state by the clinical state scale, quality of life, anxious and depressive status. The majority of patients with MR III had significant left ventricle (LV) systolic dysfunction (p=0,029), severe CHF course (p=0,034), received furosemide (p=0.004) and digoxin (p=0,004). They had significant increase in end-diastolic dimension (p<0,001), end-systolic dimension (p<0,001), left atrium (p=0,004), end-diastolic volume (p<0,001), end-systolic volume (p<0,001), pulmonary artery pressure (p<0,001), decrease in LV relative wall thickness (p=0,021) and LV ejection fraction (p<0,001). Patients of this group were hospitalized because of CHF decompensation and ischemic heart disease exacerbation more often (p=0,045).Conclusion. MR can be considered as one of sensitive predictors of LV geometry and function alteration in CHF patients and play an important role in symptoms development.
Effects of beta-blocker metoprolol on quality of life in elderly patients with chronic heart failure
I.V. Vologdina
Rational Pharmacotherapy in Cardiology , 2007,
Abstract: Aim. To study effect of cardioselective β -adrenoblocker metoprolol tartrate (in retarded formulation) on quality of life in elderly patients with chronic heart failure (CHF) of ischemic etiology.Material and methods. 78 patients with CHF class III (NYHA) were involved in the study. Patients were 81,6±0,25 y.o. in average. All patients had clinical signs of mild-to-moderate depressive disorders. Patients were split on 2 groups comparable in sex and age. Patients of the 1st group (n=43) received metoprolol tartrate (Egilok Retard), 50-100 mg/d additionally to standard therapy. Patients of the 2nd group (n=35) received only standard therapy. The somatic status was assessed before and after 1 and 3 months of therapy by clinical condition evaluated scale (CCES), 6-minute walking test, left ventricular ejection fraction (Echocardiography) as well as mental status by special tests (SMSP, BDI, Hamilton scale, C.D.Spilberger-Y.L.Hanin scale) and qualities of life (MLHFQ, SF-36).Results. Reduction of CHF class from III to II was observed in 31 (76,7%) patients of the 1st group and in 23 (65,7%) patients of the 2nd group. Tolerability of Egilok Retard was good and there were not cessations because of side effects. In 3 months of therapy severity of the somatic status according to CCES reduced more significantly in the 1st group in comparison with the 2nd group (29,5 % vs 11,5 %, p <0,001). The exercise tolerance increased higher in the 1st group comparing with the 2nd one (34%vs 17 %, respectively, p<0,001). The severity of depression reduced (according to SMSP, Hamilton scale) more significantly in the 1st group in comparison with this in the 2nd one. Quality of life also improved more significantly in the 1st group according to MLHFQ and SF-36 (physical functions, role physical functions, social function scales) at the end of therapy.Conclusion. Metoprolol tartrate (in retarded formulation) improves somatic and mental status as well as quality of life in elderly patients with CHF.
Page 1 /17046
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.